menu search

editas medicine (edit) reports q3 loss, tops revenue estimates

editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Est...

November 3, 2023, 9:47 am

editas medicine to present clinical data from the ruby and edithal trials of edit-301 at the ash 2023 annual meeting and in a company-sponsored webinar

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children's to...

November 2, 2023, 9:12 am

editas (edit) gets fda's rmat tag for gene therapy to treat scd

The FDA bestows Regenerative Medicine Advanced Therapy designation to editas' (EDIT) gene editing thera...

October 17, 2023, 1:31 pm

Is editas stock a buy now?

editas uses an untraditional gene-editing technique. The company is in the clinical stage with no appro...

October 7, 2023, 10:07 am

editas medicine: ruby gems, sparkling catalysts in sickle cell arena

editas Medicine's reduced R&D costs and strong cash position provide operational comfort but necessitat...

October 3, 2023, 2:59 am

Why editas medicine stock is soaring today

Stifel upgraded editas Medicine stock from hold to buy and raised the price target from $9 to $17. The ...

September 29, 2023, 11:21 am

1 gene editing stock to buy now, and 1 to sell

Caribou Biosciences has plenty of money for the next year or so, and great data. editas Medicine is far...

September 23, 2023, 8:45 am

editas medicine, inc. (edit) presents at wells fargo securities healthcare conference call transcript

editas Medicine, Inc. (NASDAQ:EDIT ) Wells Fargo Securities Healthcare Conference Call September 7, 202...

September 7, 2023, 7:11 pm

These 2 stocks could skyrocket by 54% and 119%, according to wall street

editas Medicine encountered problems with one of its top candidates last year, while the other still ha...

August 23, 2023, 8:25 am

editas' (edit) q2 earnings beat, sales miss, pipeline in focus

editas (EDIT) reports mixed second-quarter 2023 results. EDIT-301 studies remain on track to provide up...

August 3, 2023, 1:30 pm

editas medicine announces second quarter 2023 results conference call and corporate update

CAMBRIDGE, Mass., July 26, 2023 (GLOBE NEWSWIRE) — editas Medicine, Inc. (Nasdaq: EDIT), a clinical-s...

July 26, 2023, 11:00 am

After it fell 15% in 1 day, should you buy the dip on editas stock?

editas Medicine is issuing new stock, and that made its share price fall. The new funds will pay for le...

June 20, 2023, 10:23 am

editas medicine announces pricing of offering of common stock

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) — editas Medicine, Inc. (Nasdaq: EDIT), a clinical-s...

June 15, 2023, 2:06 am

editas (edit) surges 15.5%: is this an indication of further gains?

editas (EDIT) witnessed a jump in share price last session on above-average trading volume. The latest ...

June 14, 2023, 7:53 am

editas medicine, inc. (edit) edit-301 clinical update call transcript

editas Medicine, Inc. (NASDAQ:EDIT ) EDIT-301 Clinical Update Conference Call June 12, 2023 8:00 AM ET ...

June 12, 2023, 3:11 pm

editas (edit) posts upbeat initial data from scd & tdt studies

editas (EDIT) announces positive preliminary safety and efficacy data from patients treated with its le...

June 12, 2023, 11:13 am

Why are gene editing stocks edit, nvta, crsp up today?

An upcoming event has gene editing stocks rising today. editas Medicine (NASDAQ: EDIT ) has announced p...

June 6, 2023, 4:15 pm

editas medicine, inc. (edit) bank of america global healthcare conference call transcript

editas Medicine, Inc. (NASDAQ:EDIT ) Bank of America Global Healthcare Conference Call May 9, 2023 8:00...

May 13, 2023, 10:17 pm

editas medicine to present clinical data from the ruby trial of edit-301 for the treatment of severe sickle cell disease at the eha 2023 congress

Company-sponsored webinar to be announced CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) — editas Me...

May 11, 2023, 2:32 pm

editas medicine to present clinical data from the ruby trial of edit-301 for the treatment of severe sickle cell disease at the eha 2023 congress

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- editas Medicine, Inc. (Nasdaq: EDIT), a clinical st...

May 11, 2023, 10:32 am


Search within

Pages Search Results: